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The aim of this study was to investigate whether lower serum vitamin D metabolite levels 
were associated with altered cytokine/chemokine and metabolic hormone levels in three 
different hypertensive disorders in pregnancy (HDP). Healthy pregnancy (n = 30) and 
hypertensive disorders in pregnancy (HDP) (n = 30), i.e., gestational hypertension (GH), 
preeclampsia (PE), and eclampsia (EC) subjects were enrolled. Vitamin D metabolites 
were measured by UPLC/APCI/HRMS method. Circulatory 27 cytokines/chemokines 
and 10 metabolic hormones were measured. Significantly decreased 25(OH)D and 
1,25(OH)2D levels were observed in HDP. The levels of 25(OH)D were significantly 
lower in PE and EC, whereas the serum levels of 1,25(OH)2D significantly decreased 
only in EC subjects. Serum 25(OH)D and 1,25(OH)2D levels were negatively correlated 
with systolic- and diastolic blood pressure, creatinine, and uric acid levels. Serum 
interleukin (IL)-6 and IL-13 decreased, and GIP levels were increased in gestational 
hypertensive subjects. Platelet-derived growth factor-BB and IL-8 levels were increased 
and macrophage inflammatory protein-1beta levels were decreased in EC subjects. 
IL-8 and IL-10 increased, and rantes and GIP levels decreased in the EC group as 
compared with the GH group. Multivariate logistic regression analysis showed that 
eotaxin, monocyte chemotactic protein-1, 25(OH)D, and 1,25(OH)2D were predictors of 
HDP. Our analyses suggest that lower vitamin D metabolites are associated with altered 
cytokines/chemokines and metabolic hormones in HDP.
Keywords: cytokines, chemokines, metabolic hormones, vitamin D, eclampsia, preeclampsia, gestational 
hypertension, nutrition
inTrODUcTiOn
Hypertension is the most common medical problem encountered during pregnancy, complicat-
ing 5–10% of pregnancies (1). Gestational hypertension (GH), preeclampsia (PE), and eclampsia 
are spectrum of hypertensive disorders in pregnancy (HDP). Although these disorders can appear 
in isolation, they are progressive manifestation of a single process and thus share a common 
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etiology  (2). HDP is considered as a risk factor for future car-
diovascular diseases in later stages of life. Different mechanisms 
such as endothelial dysfunction, oxidative stress, inflammation, 
and metabolic abnormalities play important role in HDP (3). 
Serum biomarkers reflect underlying disease processes of HDP, 
i.e., increased creatinine and uric acid levels indicate renal dys-
function; diminished calcium levels reflect metabolic changes; 
and reduced placental growth factor (PIGF) indicates placental 
dysfunction (4).
Vitamin D is a secosteroid and plays pivotal role in bone 
and mineral metabolism. During pregnancy, vitamin D plays 
important role in implantation and placental function due to 
angiogenic, immunomodulatory, and anti-inflammatory effects 
(5). While still incompletely understood, the pathophysiology of 
HDP involves abnormal placentation and angiogenesis. Several 
studies have demonstrated an association between higher 
25(OH)D levels and reduced risk of HDP especially in PE (6–11). 
Many studies reported that Indian subjects are more prone to 
vitamin D deficiency despite the availability of abundant sun-
shine throughout the year in many parts of India (12–17).
Hypertensive disorders in pregnancy are characterized 
as excessive maternal inflammatory responses to pregnancy. 
Inflammation involves a complex network of cytokines released 
from stressed cells and damaged tissues (18). Cytokines/
chemokines are protein mediators that are known to be involved 
in many biological processes including cell growth, survival, 
inflammation, and differentiation (19). Limited data exist 
regarding cytokine/chemokine and metabolic hormone levels in 
subjects with hypertension disorders such as GH, PE, and EC. 
There is no study from Indian subjects to find the vitamin D 
association with circulatory cytokine/chemokine and metabolic 
hormone levels among healthy pregnancy (HP) associated with 
HDP. We inferred that vitamin D deficiency may be associated 
with systemic inflammation and could alter many cytokine/
chemokine and metabolic hormones in hypertension disorders 
in pregnant women. To test our hypothesis, we have assessed 
serum cytokines/chemokines, metabolic hormones, and vitamin 
D metabolites in the HDP group (i.e., GH, PE, and EC) and 
compared those with the HP group and found the association 
of vitamin D metabolite levels with cytokine/chemokine and 
metabolic hormones.
MaTerials anD MeThODs
study Design
Cross-sectional study consists of pregnant women (HP, gesta-
tional hypertensive PE and EC subjects) in their third trimester, 
and inclusion criteria of subjects age was 18–45  years. Blood 
samples collected from women admitted with HP, GH, PE, and 
EC at the maternity ward at Mediciti Institute of Medical Sciences 
outpatient clinic, Hyderabad, India, were used for the study. 
GH was defined as development of hypertension (i.e., systolic 
BP ≥ 140 mmHg and diastolic BP ≥ 90 mmHg) for the first time 
after mid pregnancy (after 20 weeks). PE was defined as blood 
pressure ≥ 140/90 and proteinuria ≥ +1, measured at least twice 
4–6 h apart after gestational week 20 (20). EC was defined as onset 
of convulsion in a woman with PE that cannot be attributed to 
other causes. None of the subjects had found complications with 
HELLP syndrome [A combination of the breakdown of red blood 
cells (hemolysis; the H in the acronym), elevated liver enzymes 
(EL), and low platelet count (LP) occurring in pregnancy]. HP 
group with normal BP, no proteinuria, and no systemic or endo-
crine disorder or absence of urinary tract infections were enrolled 
as control pregnant women. All healthy pregnant women will be 
in their third trimester (> 24weeks).
Women with previous PE pregnancies and who were on vitamin 
D supplements were not included. Women using acetylsalicylic 
acid or low-molecular weight heparin in the current pregnancy 
were also excluded from the study (4). Gestational age for both 
cases and controls were based on routine ultrasound examination 
between gestational week 17 and 20. Thirty serum samples from 
normal pregnant women individuals collected under informed 
consent were used as controls. Season of last menstrual period 
was defined as winter (December to February), spring (March 
to May), summer (June to August), and autumn (September to 
November).
The study was approved by the Mediciti Ethics Committee 
(Institutional). All women gave written informed consent for 
this study. The study did not include any vulnerable population. 
During the study, participants were interviewed about maternal 
age, chronic diseases, medication, ethnical origin, smoking status, 
method of conception, any previous pregnancies affected by PE 
or GH, and family history of PE.
Blood and Urine collection
Blood Sample Collection
After collection, the blood samples are allowed to stand for 
complete clot formation at room temperature and subsequently 
centrifuged for 10 min at approximately 1,500 × g. A total of 20 μL 
of each serum sample is used for creatinine and uric acid assay 
(within 3 h). Rest of the serum sample is appropriately labeled 
and stored at −80°C until batch analysis for vitamin D metabo-
lites, serum cytokine/chemokine, and metabolic hormones 
measurement.
Urine Sample collection
A total of 10 mL of early morning midstream urine samples was 
collected into appropriately labeled sterilized containers and 
analyzed immediately for urine protein.
Blood Pressure and Biochemical 
Parameter Measurement
Blood pressure was measured using oscillometric blood pressure 
monitor (model–omron HEM-780N3), calibrated prior to and 
once during the study period. Calibration of the instrument was 
checked periodically. Two measurements were taken after sitting 
comfortably on a chair for more than 5 min with left arm at the 
level of heart resting on a table. Serum creatinine levels were 
measured by modified kinetic Jaffe’s reaction in Dade Behring 
dimension Xpand plus system (creatinine flex reagent cartridge) 
according to the manufacturer’s instructions. Serum uric acid lev-
els were measured by modified uricase method in Dade Behring 
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dimension Xpand plus system (uric acid flex reagent cartridge) 
according to manufacturer’s instructions. Urinary protein levels 
have been measured by the pyrogallol red test. In brief, the 
concentration of total protein was determined by measuring 
the absorbance of colored solution at 600 nm by Systronics UV 
double beam spectrophotometry (21).
serum cytokine/chemokine and 
Metabolic hormone Measurements
Serum levels of 27 cytokines, i.e., interleukin (IL)-1beta, IL-1 
receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, Il-6, IL-7, IL-8, 
IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin, basic FGF, 
G-CSF, GM-CSF, interferon (IFN)-gamma, IFN-gamma-
inducible protein (IP)-10, monocyte chemotactic protein 
(MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-
1β, platelet-derived growth factor (PDGF)-BB, rantes, tumor 
necrosis factor (TNF)-alpha, and vascular endothelial growth 
factor (VEGF), and 10 metabolic hormones, i.e., C-peptide, 
ghrelin, GIP, GLP-1, glucagon, insulin, leptin, plasminogen-
activating factor (PAI)-1 (total), resistin, and visfatin were 
measured by using Bio-Plex Pro human cytokine Grp I panel 
27-plex (Cat#M50-0KCAF0Y) and Bio-Plex Pro human dia-
betes panel 10-plex (Cat#171-A7001M), respectively. On the 
day of experiment, frozen serum samples were thawed, mixed 
by vortexing, and then centrifuged at 10,000  rpm for 5  min 
to isolate debris. All experiments were performed according 
to the manufacturer’s instructions using handheld magnetic 
separator bloc for 96-well flat bottom plates and analyzed 
using the Bio-Plex-200 system (Bio-Rad Corp.). All cytokine/
chemokine and metabolic hormone standards were provided by 
the manufacturers. Acquisition gates were set at 8,000–15,000. 
Sample volume used for this analysis was 25 μl, and 50 events 
per bead were acquired. Mean fluoresce intensity was meas-
ured using Bio-Plex manager software version 5.0 (Bio-Rad) 
and compared to a standard curve to generate concentration 
values. Values below the range of the standard curve were set to 
the lower limit of detection. Three of the 27 cytokines analyzed 
(IL-2, GM-CSF, and IL-15) were excluded from further analy-
ses, since approximately 95% sample concentration is below 
than the lowest standard or its maximum fluorescent intensity 
value near to background. The serum samples were measured 
in a single replicate, whereas cytokine standards and blank 
samples were measured in duplicate on each plate.
UPlc/atmospheric Pressure chemical 
ionization (aPci)/hrMs Method for 
Quantification of Vitamin D and its 
Metabolite
Human serum (Biocell Laboratories, Inc., USA) was stripped 
and used as blank serum. Biocell serum was mixed with acti-
vated charcoal and agitated at room temperature overnight. The 
Biocell serum was then centrifuged at 9,000 × g for 20 min, and 
supernatant was removed and filtered. The filtered serum was 
again centrifuged at 6,000 ×  g, and the supernatant was sepa-
rated. Stripped serum was injected into the UPLC/APCI/HRMS 
method to confirm untraceable level of vitamin D3 (VitD3) and 
vitamin D2 (VitD2) and its respective metabolites such as 25(OH)
D3, 1,25(OH)2 D3, 25(OH)D2, and 1,25(OH)2 D2.
The stock solution of VitD3, VitD2, and its respective metabo-
lites were prepared in ethanol. Serial dilution was done to prepare 
the primary aliquots for calibration curve samples ranging from 3 
to 200 ng/mL for VitD3, 25(OH)D3, and VitD2 and 5–200 ng/mL 
for 1,25(OH)2 D3, 25(OH)D2, and 1,25(OH)2 D2. Similarly, low, 
middle, and high QC (LQC, MQC and HQC) samples at three 
different levels were prepared independently at concentrations of 
3 ng/mL (LQC), 10 ng/mL (MQC), and 200 ng/mL (HQC) for 
VitD3, 25(OH)D3, and VitD2. Whereas, 5 ng/mL (LQC), 10 ng/
mL (MQC), and 200 ng/mL (HQC) for 1,25(OH)2D3, 25(OH)D2, 
and 1,25(OH)2D2. All the stock solutions were stored at 0–4°C 
for further use. Stock solution of 1 mg/mL of dihydrotachysterol 
[Internal standard (IS)] was prepared in ethanol and diluted with 
methanol to prepare working solution containing a concentra-
tion of 50  ng/mL. To an aliquot of 100 μL of stripped serum, 
10 μL of 50 ng/mL IS solution was added followed by 1 mL of 
hexane:heptane:acetone in the ratio of 45:40:15. This mixture was 
thoroughly mixed, shook, and centrifuged at 6,000 × g at 4°C. 
Evaporation of supernatant was done on ScanVac speed Vacuum 
Concentrator, and 100  μL of methanol was added and 10  μL 
aliquots of sample solution were injected into the UPLC/APCI/
HRMS system for analysis.
Analysis was carried out on U-HPLC instrument (Thermo 
Scientific Accela, Germany) equipped with a quaternary pump, 
a degasser, a diode-array detector, an autosampler, and a column 
compartment. Mass spectrometric detection was carried out 
using an Orbitrap mass analyzer (Exactive Thermo Scientific, 
Germany) equipped with an APCI source. The data acquisition 
was under the control of Xcalibur software. The separation of 
vitamin D and its metabolites and IS from endogenous sub-
stances was achieved using Water’s X select CSH phenyl hexyl 
column (150 mm × 4.6 mm I.D.; particle size 3.5 μm) and mobile 
phase consisting of a mixture of ammonium formate 10 mM 
in methanol (A) and acetonitrile:acetone:IPA (5:4:1; B) in an 
gradient program mode. The gradient solvent program was set 
as follows: (Tmin/% proportion of solvent B): 0/5, 0–5/95, 5–6/5, 
and 6–8/5. The flow rate of the mobile phase was 1.00 mL/min, 
the column temperature 25°C, and the injection volume 10 μL. 
The typical operating source conditions for MS scan in positive 
ion APCI mode were optimized as follows sheath gas flow rate 
65; Aux gas flow rate 20; discharge current 10.00 μA; capillary 
temperature 300°C; capillary voltage 50  V; tube lens voltage 
85.0  V; skimmer voltage 18.00  V; and vaporizer temperature 
380°C. For quantification, EICs of [M + H]+ at m/z 385.34649, 
[M + H-H2O]+ at m/z 383.33084, and [M + H-H2O]+ at m/z 
399.32576 for VitD3, 25(OH)D3 and 1,25(OH)2D3, respectively 
with a 5  ppm range centered on the exact m/z value were 
generated. Similarly, EICs of [M + H-H2O]+ at m/z 379.33593, 
[M +  H-H2O]+ at m/z 395.33084 and [M +  H-H2O]+ at m/z 
411.32576, and [M +  H-H2O]+ at m/z 381.31519 for VitD2, 
25(OH)D2 and 1,25(OH)2D2, and IS, respectively. The devel-
oped method was validated with respect to specificity, sensitiv-
ity, linearity, precision, accuracy, matrix effect, and stability. 
Details of the method were provided briefly in our previous 
publication (22).
TaBle 1 | clinical characteristics of study population.
Variables (characteristics  
at study visit)
study groups
healthy pregnancy  
(hP, n = 30)
gestational hypertension 
(gh, n = 10)
Preeclampsia  
(n = 10)
eclampsia  
(n = 10)
Age in years (mean ± SD) 21.80 ± 2.7 22.90 ± 3.7 23.00 ± 2.4 22.00 ± 2.7
Sys BP (mmHg) (mean ± SD) 116.3 ± 6.9 144.8 ± 1.3* 153.0 ± 7.9* 158.9 ± 3.4*
Dia BP (mmHg) (mean ± SD) 76.6 ± 5.0 95.10 ± 2.9* 100.5 ± 9.5* 103.6 ± 4.6*
Gestational age in weeks (mean ± SD) 36.67 ± 3.1 34.20 ± 4.1 33.0 ± 3.1 32.7 ± 4.9
Season of last menstrual cycle, n (%)
Summer 0 (0) 0 (0) 1 (10) 2 (20)
Autumn 3 (10) 0 (0) 2 (20) 3 (30)
Spring 1 (3.3) 5 (50) 3 (30) 0 (0)
Winter 26 (86.6) 5 (50) 4 (40) 5 (50)
Proteinuria (dipstick) n.a. n.a. 2 (1–3) 2 (1–3)
Urinary microprotein (mg/dL) 7.4 (3.9–10.6) 2.2 (1.1–8.9) 131 (96.60–345.6)*,† 133.1 
(101.0–309.9)*,†
Serum creatinine (mg/dL) 0.6 (06–0.7) 0.7 (0.6–0.8) 0.8 (0.7–0.8)* 0.8 (0.9–1.0)*,†
Serum uric acid levels (mg/dL) 3.8 (3.6–4.4) 4.6 (4.4–5.7) 6.3 (4.8–6.9)* 7.6 (6.8–8.3)*,†
*p < 0.05 compared to HP.
†p < 0.05 compared to GH.
n.a., not applicable.
Mean ± SD for normally distributed variables and median with interquartile range for non-normally distributed data. Comparisons between outcome groups Kruskal–Wallis and 
Dunn’s test for continuous variables.
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statistical analyses
Descriptive statistics of non-normally distributed data was 
reported as median (interquartile range), while normally distrib-
uted data were represented as mean ± SD and categorical variables 
as number (percentages). Data were tested for normality using 
the Kolmogorov–Smirnov test. Non-normal data were analyzed 
by Kruskal–Wallis test and Dunn’s test for pairwise comparisons. 
Spearman’s rank correlation coefficient was used to test for cor-
relations between serum vitamin D metabolite levels and serum 
cytokine/chemokine and metabolic hormones with Bonferroni 
adjustment of multiple analysis. Univariate and multivariable 
logistic regression analyses were performed to identify covari-
ates as potential confounders on the basis of their significance 
(p <  0.05). ORs with 95% CIs were used to report the results. 
Figures and tables were generated using GraphPad Prism v.5.0 
and Matlab v.r2013b. SAS® V.9.4 software was used for all other 
statistical analyses.
resUlTs
clinical characteristics of the study 
Population
Table 1 describes about the clinical characteristics of the study 
population. In the present study, 30 healthy pregnant women 
and 30 HDP (10 gestational hypertensive disorders, 10 PE, and 
10 EC) subjects were enrolled for the study. Women participants’ 
age is ranging from 19 to 30  years. As expected, systolic and 
diastolic blood pressures were significantly higher in three 
different HDP as compared with the HP group (Table  1). In 
winter season, pregnant women with hypertension disorders 
were approximately 50% as compared to the other seasons. 
However, our data found 86.6% of healthy pregnant women 
are from winter season as compared to other seasons. Urinary 
microprotein levels significantly (p < 0.05) increased in PE and 
EC subjects as compared with the HP group and GH group. 
Serum uric acid and creatinine levels significantly (p <  0.05) 
increased in PE and EC subjects as compared with the HP group 
and significantly increased (p <  0.05) in EC as compared with 
the gestational hypertensive disorders group (Table 1).
Distribution of 25(Oh)D levels in normal 
Pregnant Women and hypertensive 
Disorders in Pregnant Women
Distribution of total 25(OH)D levels in all subjects is mentioned 
in Figure  1. The median total 25(OH)D concentrations in the 
total subjects was 41.2 ng/mL (28.2–51.5) (Figure 1A). According 
to the previous literature, serum total 25(OH)D concentrations 
were well categorized as adequate (> 30 ng/mL) and inadequate 
<30 ng/mL (23).
In the present study, 96.6% of normal healthy pregnant 
women and 46.6% of hypertension disorders of pregnant 
women have adequate (> 30 ng/mL) level of 25(OH)D. A total 
of 3.3% of HP group and 53.3% of hypertensive disorders in 
pregnant women have inadequate (<30 ng/mL) level of 25(OH)
D (Figure 1B).
Vitamin D Metabolite levels in 
hypertensive Disorders in Pregnant 
Women
Total 25(OH)D is evaluated by sum of 25(OH)D + 25(OH)D3, 
and total 1,25(OH)2D is evaluated by sum of 1,25(OH)2D2 + 
1,25(OH)2D3. Total 25(OH)D and total 1,25(OH)2D levels were 
decreased significantly (p <  0.05) in HDP group as compared 
with healthy pregnant group (Figures 2A,B).
Five vitamin D metabolites, i.e., VitD3, 25(OH)D3, 1, 25(OH)2 
D3, VitD2, and 1,25(OH)2D2 levels were significantly (p < 0.05) 
lower in the HDP group as compared with the HP group (Figures 
S1A–D,F in Supplementary Material). However, 25(OH)D2 did 
FigUre 2 | Vitamin D metabolite (a) 25(Oh)D and (B) 1,25(Oh)2D levels in combined hypertension disorders in pregnancy (hDP) as compared to 
healthy pregnancy (hP). **p < 0.01, ***p < 0.001 vs HP. The Mann–Whitney U test and Student’s t test were used.
FigUre 1 | (a) Distribution of serum 25(OH)D concentrations in total subjects. (B) Distribution of 25(OH)D levels in healthy pregnancy (HP) and Hypertension 
disorders in pregnancy (HDP). Distribution of 25(OH)D levels according to serum concentrations, i.e., adequate (> 30 ng/mL) and inadequate (<30 ng/mL).
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not show any alteration between the study groups (Figure S1E in 
Supplementary Material).
Vitamin D Metabolite levels in normal 
Pregnant Women, gh, Pe, and ec
Vitamin D metabolites from each hypertension disorder group 
were analyzed and compared with the HP group. Serum 25(OH)
D levels were gradually decreased in three hypertensive disorders, 
i.e., GH, PE, and EC. However, significant (p < 0.05) reduction 
was observed only in PE and EC groups as compared with the 
HP group (Figure 3A). Serum 1,25(OH)2D levels were (p < 0.05) 
significantly decreased only in EC as compared with the HP 
group (Figure 3B).
Vitamin D3 levels significantly (p <  0.05) decreased in GH, 
PE, and EC subjects as compared with the HP group (Figure S2A 
in Supplementary Material). 25(OH)D3, VitD2, and 1,25(OH)2D2 
levels significantly decreased in PE subjects as compared with the 
HP group (Figures S2B,D,F in Supplementary Material). VitD2 
levels significantly (p < 0.05) decreased in EC subjects as com-
pared with the gestational hypertensive subjects (Figure S2D in 
Supplementary Material). However, any alteration of 25(OH)D2 
levels in hypertensive disorders in pregnant women was not found 
as compared with the HP group (Figure S2E in Supplementary 
Material).
serum cytokine/chemokine and 
Metabolic hormone Profiles in hP, gh, Pe, 
and ec subjects
Alteration of cytokines/chemokines and metabolic hormones has 
been compared among four groups. Serum levels of cytokine/
chemokine and metabolic hormones are shown in Table  2. 
Fold change expressions of circulatory cytokine/chemokine and 
metabolic hormones are shown in Figure 4. Gestational hyper-
tensive subjects have significantly lower serum IL-6, IL-13, and 
higher GIP levels as compared with the HP group. Surprisingly, 
there was no significant alteration of cytokine/chemokine and 
metabolic hormone levels in PE subjects as compared with the 
HP group. Serum IL-8 and PDGF-β levels significantly increased 
and MIP-1β levels decreased in EC subjects as compared with the 
HP. All serum parameters of PE and EC patients were compared 
TaBle 2 | serum cytokine and metabolic hormone levels in study groups.
Variables (pg/ml) healthy pregnancy  
(hP, n = 30)
gestational hypertension  
(gh, n = 10)
Preeclampsia  
(Pe, n = 10)
eclampsia  
(n = 10)
Interleukin (IL)-1β 2.04 (1.79–2.43) 1.82 (1.39–2.17) 2.04 (1.28–2.37) 1.65 (1.33–2.65)
IL-1 receptor antagonist 80.3 (70.6–110.9) 70.7 (59.8–79.4) 83.9 (65.2–101.8) 80.6 (49.7–113.1)
IL-4 1.96 (1.74–2.39) 1.70 (1.70–1.93) 2.12 (1.66–2.35) 2.13 (1.38–2.43)
IL-5 15.04 (12.6–16.8) 11.3 (8.55–15.9) 14.31 (9.73–17.19) 12.83 (9.16–17.85)
IL-6 4.72 (3.83–8.55) 2.425 (1.60–4.74)* 4.05 (2.21–7.12) 6.46 (3.72–9.18)
IL-7 26.87 (25.40–31.80) 23.15 (26.21–35.82) 31.31 (26.21–35.82)† 24.57 (19.95–4,032)
IL-8 12.76 (11.08–15.82) 10.28 (8.94–13.50) 15.34 (10.28–22.19) 18.71 (15.48–22.96)*, †
IL-9 24.08 (18.23–30.23) 21.63 (18.65–33.25) 22.47 (20.17–26.76) 26.06 (16.71–29.45)
IL-10 2.46 (1.44–4.27) 1.60 (0.91–2.42) 2.81 (1.99–8.01) 5.99 (2.39–10.05)†
IL-12 4.45 (3.19–9.09) 3.54 (2.68–6.95) 4.94 (2.76–11.07) 4.69 (0.88–11.68)
IL-13 41.86 (33.23–55.14) 25.27 (20.24–34.03)* 44.98 (34.03–55.10)† 30.92 (22.89–38.21)
IL-17 26.04 (16.42–38.13) 19.54 (14.92–25.13) 24.81 (20.75–38.23) 12.96 (6.025–29.63)
Eotaxin 50.38 (40.96–59.86) 56.89 (36.94–66.81) 51.78 (47.90–57.01) 53.15 (44.04–58.95)
FGF-basic 28.60 (15.35–42.35) 28.00 (21.06–38.56) 18.88 (8.93–32.44) 16.86 (15.35–29.77)
G-CSF 41.85 (37.29–48.28) 36.33 (31.74–38.13) 39.69 (34.64–52.30) 43.05 (32.10–50.28)
Interferon-gamma 145.0 (125.5–187.6) 120.5 (102.1–134.5) 148.3 (135.3–161.0) 121.9 (95.19–164.1)
IFN-gamma-inducible protein (IP)-10 1,247 (789.5–2,010) 914.5 (660.9–1,472) 932.4 (725.4–1,254) 1,187 (736.2–1,946)
Monocyte chemotactic protein -1 11.96 (7.2–15.75) 8.30 (7.42–10.22) 7.42 (6.15–8.30) 8.94 (3.2–12.32)
Macrophage inflammatory protein 
(MIP)-1α
2.21 (1.77–3.15) 2.26 (1.54–3.08) 2.14 (1.08–2.64) 2.07 (1.52–2.74)
Platelet-derived growth factor-BB 3,558 (2,757–4,597) 3,712 (3,117–4,385) 4,345 (3,204–5,884) 4,931 (4,493–6,098)*
MIP-1β 60.80 (48.85–78.97) 57.86 (45.99–75.21) 56.20 (39.09–70.96) 35.45 (30.31–53.31)*
Rantes 22,415 (17,813–26,419) 28,781 (20,391–29,826) 21,041 (20,394–24,885) 20,329 (15,136–21,372)†
Tumor necrosis factor-α 29.15 (23.63–34.76) 27.30 (21.82–33.82) 24.54 (20.46–25.46) 27.31 (17.34–34.30)
Vascular endothelial growth factor 3.285 (2.19–4.38) 2.33 (1.64–5.71) 4.46 (2.33–5.62) 4.14 (2.98–6.39)
C-peptide 2,157 (1,098–3,464) 3,109 (1,657–6,013) 2,438 (1,086–5,252) 1,601 (1,243–2,938)
Ghrelin 574.3 (448.7–777.6) 539.3 (400.2–657.4) 507.3 (432.1–668.4) 517.0 (450.9–656.2)
GIP 362.0 (243.5– 498.4) 670.3 (571.3–1,116)* 411.1 (306.5–875.3) 373.0 (203.6–425.0)†
GLP-1 296.3 (267.8–326.1) 290.7 (263.7–320.4) 273.3 (238.5–284.9) 246.3 (233.9–331.3)
Glucagon 298.3 (279.5–329.4) 303.8 (271.7–318.9) 310.6 (280.7–330.0) 289.4 (252.5–308.0)
Insulin 1,155 (646.5–2,305) 1,275 (788.7–4,890) 725.6 (543.9–1,932) 718.1 (428.3–1,420)
Leptin 11,068 (4,872–19,974) 12,913 (8,028–21,469) 12,015 (8,297–29,339) 12,588 (3,447–46,832)
Plasminogen-activating factor-1 1,02,521 (75,285–1,64,409) 116,552 (98,060–306,583) 1,41,578 (84,497–2,33,429) 170,343 (118,350–240,203)
Resistin 9,584 (6,531–12,557) 7,119 (5,474–9,264) 12,765 (10,003–18,040)† 9,025 (6,421–12,162)
Visfatin 1,469 (1,186–2,314) 1,492 (1,224–2,449) 1,732 (1,488–2,389) 1,561 (1,163–1,937)
Continuous variables are reported as median (25th–75th percentile) as not found normally distributed. Comparisons between outcome groups by the Kruskal–Wallis and Dunn’s 
tests.
*p < 0.05 compared to HP.
†p < 0.05 compared to GH.
FigUre 3 | Vitamin D metabolites (a) 25(Oh)D and (B) 1,25(Oh)2D in gestational hypertension (gh), preeclampsia (Pe), and eclampsia (ec) as 
compared to the healthy pregnancy (hP) group. **p < 0.01, ***p < 0.001 vs HP. For comparisons between outcome groups, the Kruskal–Wallis and Dunn’s 
tests were used.
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with the GH group. IL-7, IL-13, and resistin levels significantly 
increased in PE subjects as compared with gestational hyperten-
sive subjects. Serum rantes and GIP levels significantly decreased, 
and IL-8, IL-10 levels significantly increased in EC subjects as 
compared with the gestation hypertensive subjects. However, no 
significant changes in any serum parameters between PE and EC 
FigUre 4 | cytokine/chemokine and metabolic hormones expression: fold change expression of 34 analytes in gestational hypertension (gh), 
preeclampsia (Pe), eclampsia (ec) compared to healthy pregnancy (hP) obtained by Bio-Plex assay. Values more than 0 represent upregulation and less 
than 0 downregulation in three hypertension disorder groups, i.e., GH, PE, and EC. *<0.05 vs HP, †0.05 vs GH.
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subjects (Table 2) were found. Significant alterations of cytokines/
chemokines IL-1ra, IL-4, IL-5, IL-7, IL-9, IL-12, eotaxin, G-CSF, 
IFN-γ, IP-10, MIP-1α, TNF-α, VEGF, and metabolic hormones 
C-peptide, ghrelin, GIP, GLP-1, glucagon, leptin, and visfatin 
levels were not found in our study groups (Table 2). Significant 
alteration of plasma cytokine/chemokine and metabolic hormone 
levels among four groups, i.e., GH, PE, EC, and HP subjects is 
presented in Figures S3A–J in Supplementary Material.
serum cytokine/chemokine and 
Metabolic hormone Profiles in combined 
hypertensive Disorders of Pregnancy as 
compared with the hP group
In the present study, serum cytokine/chemokine and metabolic 
hormone levels in the combined hypertensive disorders group 
were compared with the HP group. Cytokine/chemokine IL-1ra, 
IL-6, IL-13, IFN-γ, MCP-1, MIP-1β levels and metabolic hor-
mone such as GLP-1 levels significantly (p <  0.05) decreased 
in pregnant women with hypertensive disorders as compared 
with the HP group (Table 3). Serum PAI-1 and GIP levels were 
increased in the hypertension disorders group as compared with 
the HP group (Table 3).
correlations between Vitamin D 
Metabolites and cytokine/chemokine, 
Metabolic hormones, clinical 
characteristics, and laboratory 
Parameters
Correlations between vitamin D metabolites with various clinical 
parameters, cytokines/chemokines and metabolic hormones are 
presented in Table 4. There were significant negative correlation 
between 25(OH)D and parameters like SBP (r = −0.625, p < 
0.0001) and DBP (r = −0.632, p < 0.0001) in overall subjects 
(Table 4; Figure S4 in Supplementary Material), similarly, serum 
creatinine (r = −0.470, p < 0.0001) and serum urea levels (r = 
−0.528, p < 0.0001) were also negatively correlated with 25(OH)
D. Also, significant negative correlations were observed between 
1,25(OH)2D and parameters like SBP (r = −0.449, p = 0.0003) 
and DBP (r = −0.425, p = 0.0007) in overall subjects (Table 4). 
Significance was reported with Bonferroni adjustment taking 
into account for multiple testing.
When significance was considered as p < 0.05, total 25(OH)
D shows positive correlation with MCP-1 (r = 0.274, p = 0.0405), 
MIP-1α (r = 0.350, p = 0.0076), MIP-1β (r = 0.273, p = 0.0343), 
and TNF-α (r = 0.342, p = 0.0097) levels. Significant (p < 0.05) 
negative correlations were observed between 1,25(OH)2D 
with serum creatinine (r = −0.354, p =  0.0054), serum urea 
(r = −0.272, p = 0.0352), and ghrelin (r = −0.264, p = 0.0409) 
levels, while positive correlations were observed between 
1,25(OH)2D and parameters such as IL-9 (r = 0.257, p = 0.0470), 
IL-17 (r =  0.259, p =  0.0450), INF-γ (r =  0.267, p =  0.0386), 
and MIP-1β (r = 0.331, p = 0.0409) levels (Table 4). However, 
correlation between vitamin D metabolites and inflammatory 
markers was not found significant taking Bonferroni adjustment 
into account for multiple testing.
groupwise correlations between Blood 
Pressure Parameters and circulatory 
Markers
Correlation analysis, between 25(OH)D with various blood 
pressure parameters in hypertension disorder groups, reveals 
TaBle 3 | serum cytokine/chemokine and metabolic hormone levels in healthy pregnancy (hP) and hypertension disorder in pregnancy.
Variables (characteristics at study visit) 
(pg/ml)
hP (n = 30) hypertension disorders in  
pregnancy (n = 30)
Interleukin (IL)-1β 2.04 (1.79–2.43) 1.87 (1.39–2.26)
IL-1 receptor antagonist 90.58 (71.7–110.9) 70.07 (59.8–96.73)a
IL-4 1.96 (1.74–2.39) 1.83 (1.43–2.32)
IL-5 15.04 (12.6–16.8) 12.46 (8.57–16.4)
IL-6 4.72 (3.83–8.6) 4.16 (2.16–7.10)a
IL-7 26.87 (25.40–31.80) 25.23 (21.44–34.02)
IL-8 12.76 (11.08–15.82) 14.48 (10.28–20.31)
IL-10 2.53 (1.54–4.42) 2.53 (1.99–7.21)
Il-12 4.45 (3.195–9.09) 3.72 (2.68–8.16)
IL-9 24.08 (18.23–30.23) 22.08 (19.48–27.39)
IL-13 41.86 (33.23–55.14) 31.19 (23.94–40.08)a
IL-17 26.04 (16.42–38.13) 22.37 (14.92–29.42)
Eotaxin 50.38 (40.96–59.86) 54.12 (43.19–58.72)
FGF-basic 28.60 (15.35–42.35) 22.73 (15.75–33.17)
G-CSF 41.85 (37.29–48.28) 39.69 (32.95–44.00)
Interferon (IFN)-gamma 145.0 (125.5–187.6) 135.3 (102.1–157.8)a
IFN-gamma-inducible protein (IP)-10 1,247 (789.5–2,010) 978 (699.6–1,428)
Monocyte chemotactic protein-1 11.96 (7.2–15.75) 7.16 (5.93–10.75)a
Macrophage inflammatory protein (MIP)-1α 2.21 (1.77–3.15) 2.07 (1.52–2.74)
Platelet-derived growth factor-BB 3,558 (2,757–4,597) 4,295 (3,242–5,326)
MIP-1β 60.80 (48.85–78.97) 54.06 (33.49–60.07)a
Rantes 22,415 (17,813–26,419) 21,170 (20,197–27,703)
Tumor necrosis factor-alpha 29.15 (23.63–34.76) 25.46 (20.01–30.08)
Vascular endothelial growth factor 3.285 (2.19–4.38) 3.83 (2.19––5.79)
C-Peptide 2,157 (1,098–3,464) 1,897 (1,447–4,650)
Ghrelin 574.3 (448.7–777.6) 517.8 (446.7–606.7)
GIP 362.0 (243.5– 498.4) 443.4 (317.3–830.3)a
GLP-1 296.3 (267.8–326.1) 271.1 (242.8–316.7)a
Glucagon 298.3 (279.5–329.4) 300.7 (271.7–318.9)
Insulin 1,155 (646.5–2,305) 913.3 (552.2–2,248)
Leptin 11,068 (4,872–19,974) 12,913 (7,738–28,037)
Plasminogen-activating factor-1 102,521 (75,285–1,64,409) 1,47,652 (1,01,855–2,40,203)a
Resistin 9,584 (6,531–12,557) 9,318 (6,095–12,101)
Visfatin 1,469 (1,186–2,314) 1,612 (1,254–2,070)
Continuous variables are reported as median (25th–75th percentile). Mann–Whitney U test was used to determine statistical significance.
aSignificant at 5% level.
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that only 25(OH)D is negatively associated with SBP (r = −0384, 
p =  0.0362) and not with DBP (Figure S5 in Supplementary 
Material). However, there is no association found between 
25(OH)D and SBP, DBP in healthy pregnant group (Figure S6 in 
Supplementary Material).
Correlation analysis between blood pressure parameters and 
circulatory markers in the HP group shows that only diastolic 
blood pressure is negatively correlated with INF-γ (r = −0.540, 
p =  0.0020) with Bonferroni adjustment for multiple testing. 
Similarly, in the hypertensive group, systolic blood pressure 
was positively associated with urinary microprotein (r = 0.712, 
p < 0001), serum creatinine (r = 0.667, p < 0.0001), and serum 
urea (r =  0.664, p <  0.0001). The diastolic blood pressure of 
the disease group positively correlated with serum creatinine 
(r = 0.607, p < 0.0004) and serum urea (r = 0.548, p < 0.0017) 
levels (Table 5).
However, considering the significance with (p < 0.05), SBP is 
positively correlated with serum creatinine (r = 0.487, p < 0.0063) 
and negatively correlated with INF-γ (r = −0.445, p = 0.0135) and 
VEGF (r = −0.424, p < 0.0243) in the HP group. DBP correlated 
with IL-1ra (r =−0.369, p < 0.0483), IL-5 (r = −388, p < 0.0374), 
TNF-α (r  =  −0398, p  <  0.0393), and VEGF (r  =  −0.421, 
p < 0.0256) in the HP group. In the hypertension disorders group, 
significantly SBP is negatively correlated with IL-6 (r =  0.447, 
p <  0.0133) and IL-10 (0.556, p <  0.0048). DBP is positively 
correlated with UMP (r = 0.515, p < 0.0035), IL-10 (r = 0.434, 
p < 0.0341), and GM-CSF (r = 0.474, p < 0.0221) and negatively 
correlated with FGF-basic (r = −0.430, p < 0.0358) (Table 5).
Fold change alteration of cytokine/
chemokine and Metabolic hormones 
Pattern among Three hDP groups
In the previous section, it is shown that the several significant 
markers perturbed in different hypertension disorder groups 
as compared with the HP group. To identify more biologically 
relevant parameters perturbed in disease condition, two criterion 
were used (i) alteration should be statistically significant (p < 0.05) 
and (ii) fold change should be ≥ 1.4. Both criteria were used to 
eliminate background noise to identify markers for specific 
TaBle 5 | groupwise correlations between blood pressure parameters 
and circulatory markers of all study subjects.
correlation 
coefficient
p-Value
healthy pregnancy variables
SBP vs serum creatinine 0.487 0.0063
SBP vs interferon-gamma (INF-γ) −0.445 0.0135
SBP vs vascular endothelial growth factor (VEGF) −0.424 0.0243
DBP vs interleukin 1 receptor antagonist −0.369 0.0483
DBP vs interleukin (IL)-5 −0.388 0.0374
DBP vs IFN-γ −0.540 0.0020
DBP vs tumor necrosis factor-alpha −0.398 0.0393
DBP vs VEGF −0.421 0.0256
hypertension disorders in pregnancy variables
SBP vs UMP 0.712 <0.0001
SBP vs serum creatinine 0.667 <0.0001
SBP vs serum urea 0.664 <0.0001
SBP vs IL-6 0.447 0.0133
SBP vs IL-10 0.556 0.0048
SBP vs 25(OH)D −0.384 0.0357
DBP vs UMP 0.515 0.0035
DBP vs serum creatinine 0.607 0.0004
DBP vs serum urea 0.548 0.0017
DBP vs IL-10 0.434 0.0341
DBP vs FGF-basic −0.430 0.0358
DBP vs GM-CSF 0.474 0.0221
Bold letters represents statistical significance taking Bonferroni adjustment into 
account.
TaBle 4 | correlations between vitamin D metabolites and circulatory 
markers of all study subjects.
Variables correlation 
coefficient 
p-Value
25(OH)D vs SBP −0.625 <0.0001
25(OH)D vs DBP −0.632 <0.0001
25(OH)D vs UMP −0.348 0.0064
25(OH)D vs serum creatinine −0.470 <0.0001
25(OH)D vs serum urea −0.528 <0.0001
25(OH)D vs monocyte chemotactic protein-1 0.274 0.0405
25(OH)D vs macrophage inflammatory protein (MIP)-1α 0.350 0.0076
25(OH)D vs MIP-1β 0.273 0.0343
25(OH)D vs tumor necrosis factor-alpha 0.342 0.0097
1,25(OH)2D vs SBP −0.449 0.0003
1,25(OH)2D vs DBP −0.425 0.0007
1,25(OH)2D vs serum creatinine −0.354 0.0054
1,25(OH)2D vs serum urea −0.272 0.0352
1,25(OH)2D vs interleukin (IL)-9 0.257 0.0470
1,25(OH)2D vs IL-17 0.259 0.0450
1,25(OH)2D vs interferon-γ 0.267 0.0386
1,25(OH)2D vs MIP-1β 0.331 0.0096
1,25(OH)2D vs ghrelin −0.264 0.0409
Bold letters represents statistical significance taking Bonferroni adjustment into 
account.
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disease condition. When we consider only fold change ≥  1.4 
as criteria, IL-6, IL-10, IL-13, MCP-1, VEGF, C-peptide, and 
GIP levels were altered in GH as compared with the HP group 
(Figure 5). However, very few markers such as IL-6, IL-13, and 
GIP levels were matched with the abovementioned two criteria. 
Similarly, when only fold change cutoff was considered, IL-10, 
IL-12, FGF-basic, MCP-1, and insulin were altered in PE sub-
jects as compared with the HP group (Figure 5). However, no 
markers were identified after consideration of both the cutoffs. 
Considering only fold change cutoff, IL-8, IL-10, IL-17, FGF-
basic, MIP-1β, insulin, and PAI-1 markers were identified in EC 
subjects as compared with the HP group (Figure 5). However, 
after applying both fold change and significance cutoff, only 
IL-8, IL-10, and MIP-1β were altered. Our results indicate that 
fold change cutoff ≥  1.4 is proved to be a better eliminator of 
background noise as there were fewer markers left after making 
a fold change cutoff of ≥ 1.4 as compared to using significance 
cutoffs (Table 1). As the fold change level increases to that of ≥ 2, 
the number of markers significantly decreases. Parameters that 
change in the significance level along with the fold change cutoffs 
provide list of biomarkers that imply inflammatory signaling 
pathways and functional involvement of hypertensive disorders 
of pregnant women.
logistic regression analysis
Multivariable–multivariate logistic regression analyses were 
performed to test the association of the vitamin D metabolites 
and cytokine/chemokine and metabolic hormones with the 
presence of HDP. Table 6 shows various models using univari-
ate and multivariable–multivariate logistic regression analyses. 
The unadjusted univariate analysis shows that INF-γ [OR 0.98 
(CI 0.96–0.99) p  =  0.0344], MCP-1 [OR 0.87 (CI 0.77–0.98) 
p = 0.0237], 25(OH)D [OR 0.88 (CI 0.88–0.94) p = 0.0001], and 
1,25(OH)2D [OR 0.62 (CI 0.44–0.86) p = 0.0044] were found to 
be significant. However, univariate adjusted analysis reveals that 
IL-17 [OR 0.93 (0.88–0.99) p = 0.0229], MCP-1 [OR 0.76 (0.628–
0.927) p = 0.0066], 25(OH)D [OR 0.83 (0.80–0.95) p = 0.0016], 
and 1,25(OH)2D [OR 0.67 (0.46–0.98) p = 0.0370] were found to 
be significant when adjusted with gestational age and season of 
last menopausal period. Two multivariable-adjusted models are 
shown in Table 6 adjusted with gestational age and season of last 
menopausal period. In the model 1, eotaxin [OR 1.07 (1.01–1.13) 
p = 0.0092], MCP-1 [OR 0.681 (0.479–0.966), p = 0.0315], and 
25(OH)D [OR 0.857 (0.758–0.969) p = 0.0141] were predictors of 
HDP, whereas model 2 confirms that eotaxin [OR 1.06 (1.01–1.11) 
p = 0.0154] and MCP-1 [OR 0.703 (0.546–0.904), p = 0.0060] are 
predictors of HDP with 1, 25(OH)2D [OR 0.457 (0.239–0.876) 
p = 0.0023].
DiscUssiOn
Hypertensive disorders of pregnancy are more common and 
morbid complications of pregnancy. GH is the early stage of 
hypertension, and PE is a combination of PE with proteinuria. 
EC is the advance and severe phase of PE. The mechanisms that 
are underlying the disease causation and progression are largely 
unknown. There are currently no early diagnostic tests that 
can identify women at increased risk. Many studies previously 
reported that low levels of vitamin D have been found in both 
males and females. However, the prevalence is higher among 
females and this may increase the risk of different pregnant 
disorders including PE (7). The link between lower vitamin 
D levels and hypertension has already been reported. Lower 
FigUre 5 | heat map provides a graphical representation of the secretary cytokine/chemokine and metabolic hormones pattern showing a fold 
change cutoff of ≥1.4 in three hypertension disorders (gestational hypertension, preeclampsia, and eclampsia) in pregnant women as compared to 
the healthy pregnancy group. Hypertension disorder groups represented in y-axis and cytokine/chemokine and metabolic hormones on x-axis. 1 represents 
upregulated parameters and −1 represents downregulated. Changes in markers are indicated using the following colors: dark blue, significantly downregulated; light 
blue, non-significantly downregulated; dark red, significantly upregulated; light red, non-significantly upregulated.
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vitamin D was associated with hypertension in different popula-
tion (24–26). Thus, there is a high possibility that lower vitamin 
D levels may also increase hypertension in pregnant women. In 
the present study, we measured six vitamin D metabolites in the 
HP group and three hypertensive disorders in pregnant women, 
i.e., GH, PE, and EC. Significant decrease in all vitamin D 
metabolite levels were observed in pregnant women with hyper-
tensive disorders except 25(OH)D2. Total 25(OH)D decreased 
significantly in PE and EC as compared with the HP group. 
However, the active vitamin D metabolites, i.e., 1,25(OH)2D 
levels, significantly decreased only in EC subjects. Overall, our 
data confirming that vitamin D deficiency may contribute to the 
development of hypertensive disorders in pregnant women. Our 
results were consistent with previous results, which reported that 
VitD3 levels significantly decreased in PE and EC subjects (27), 
and lower maternal vitamin D deficiency is the independent risk 
factor for the PE (7). It could also be possible that decreased 
vitamin D levels might be due to hypertension-produced stress 
on the kidney. Impaired renal function may cause the decrease 
in the levels of vitamin D in blood. However, in our study we 
have not included subjects with kidney problem and none of 
the pregnant women have creatinine levels > 1.5 mg/dL. Thus, 
the possibility to find lower vitamin D metabolite levels in 
hypertensive disorder patients due to the stress or mild injury 
of kidney is much less.
Vitamin D plays a crucial role in controlling anti-inflammatory 
and pro-inflammatory cytokines balance (28). Previous literature 
reported that adequate vitamin D level is essential for the pre-
vention of inflammatory diseases by modulating many genetic, 
immune, and inflammatory responses through vitamin D 
receptors (VDRs) (29–31). VDR is widely presented in all tissues 
in the body including macrophages, neutrophils, dendritic cells, 
and T-lymphocytes. The availability of VDR in the immune cells 
confirms that vitamin D plays a pivotal role in functioning in the 
immunity system including regulation of cytokine environment 
(32). Many mechanisms were involved in the prevention or delay-
ing the progression of PE. One of the important mechanisms 
that proposed is related to a defective control of effector T cells 
by regulatory T cells, which may cause poor placental invasion 
and lead to release placental-derived vasoconstrictor factors. 
All these factors promote and enhance maternal hypertension 
and proteinuria (33, 34). As vitamin D plays an important role 
in maintaining and restoring immune homeostasis and toler-
ance, the availability and effectiveness of calcitriol may directly 
regulate the immune cell function in HDP (33, 35). Another 
hypothesis is that lower vitamin D provides hypertensive effect 
through activation of renin–angiotensin–aldosterone system 
(RAAS). There are several human studies reported that increased 
circulatory levels of renin and angiotensin II associated with 
hypertension (36, 37). The molecular mechanism of vitamin 
D in the RAAS inhibition is through the suppression of renin 
expression by liganded VDR through binding to the transcription 
factor cAMP-response element-binding protein (38). Therefore, 
RAAS activation may cause abnormal endothelial function 
and is responsible for hypertensive disorder in pregnancy (39). 
Similarly, increased inflammatory cytokine levels may trigger 
endothelial dysfunction. 1,25(OH)2D3 acts directly with VDR on 
the T  lymphocyte to inhibit its proliferation (40, 41). Recently, 
researchers also reported that 1,25(OH)2D3 inhibits production 
of pro-inflammatory cytokines such as IFN-γ, IL-17, and IL-21 
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in CD4+CD25− T lymphocytes (42). Thus, lower vitamin D levels 
observed in the HDP group independently regulate hypertension 
in pregnancy and inflammation. However, we cannot comment 
on whether inflammation caused by lower vitamin D levels influ-
ences hypertension.
Cytokines/chemokines are cell signaling molecules play 
important role in modulating all immune responses. In general, 
cytokine/chemokine present in circulation picomole concentra-
tion but may increase to more than 1,000-fold during inflammation 
condition (43). A group of cytokines work as pro-inflammatory 
while others work as anti-inflammatory modulators. GH, PE, 
and EC are excessive maternal inflammatory responses to preg-
nancy (4). In the present study, 27 cytokines/chemokines and 10 
metabolic hormones were measured to know the alteration in 
HDP. IL-6 and IL-13 levels significantly decreased in combined 
hypertension disorders when compared with normal pregnant 
women. In individual hypertension disorders, significantly lower 
levels of IL-6 and IL-13 were observed only in the GH group but 
not in PE and EC groups when compared with normal pregnant 
women. Unlike our study, Tangeras et al. did not find IL-6 altera-
tion in GH and PE patients as compared with normal pregnant 
women (4). It could be possible that decrease in the IL-6 levels 
in GH is an immediate acute phase response to the early-stage 
hypertension, and these levels were further improved gradually 
in the PE and EC groups. IL-6 may act as both pro-inflammatory 
and anti-inflammatory cytokines (44) and control angiogenic 
balance and endothelial regulation in hypertensive pregnant 
women (45). Similarly, decreased IL-13 levels in the GH group 
and then increased levels in PE as compared to GH indicate 
compensatory responses to modulate the inflammation in HDP 
(46). Pro-inflammatory cytokine IL-8 levels increased in PE and 
EC subjects as compared to the normal pregnant women. This is 
consistent with the previous data reported by Tosun et al., where 
IL-8 level was higher in severe PE as compared with control 
and mild PE (47). These findings suggest that IL-8 may increase 
with severity of HDP. Similarly, IL-10 levels gradually increased 
from mild to severe hypertension disorder groups. However, 
significant changes were observed in the EC group as compared 
to the GH. Previous studies reported contradictory data in the 
circulatory IL-10 levels. While some reported higher levels of 
IL-10 in PE (48), whereas others reported lower (49–51). This 
variation in different studies might be due to sampling in different 
stages of pregnancy. IL-10 plays an important role in reduction 
of excessive inflammation by inhibiting IL-1, IL-6, IL-12, TNF-
α, and chemokines. IL-10 works as a protective agent during 
inflammation (52). IL-10 regulates maternal immunity through 
maintenance of uterine NK  cell and reduces their cytotoxic 
functions in response to pro-inflammatory challenges during 
pregnancy (53–55). Furthermore, increased IL-10 production in 
decidual Treg cells may inhibit immune stimulation of T  cells 
(56). In the present study, increased IL-10 levels in hypertension 
disorders, i.e., EC in pregnant women might be due to protective 
responses against inflammation.
Increased PDGF-BB levels were observed in EC subjects as 
compared with the HP group. Increased PDGF-BB levels play 
an important role in the vascular structural changes associated 
with hypertension (57). Our data showed that PDGF-BB levels 
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increased gradually as the severity of the hypertension disorders 
increases.
When we considered all significant (p < 0.05) altered param-
eters with a ≥  1.4 fold change, inflammatory markers such as 
IL-6, IL-13, MCP-1, and metabolic hormones such as GIP and 
C-peptide play important role in GH. However, we could not 
detect any markers that altered in PE. In case of EC, IL-8 and 
MIP-1β play major role for the pathogenesis. This clearly indi-
cates that inflammation plays a crucial role in HDP and these 
alterations were more in early hypertension disorders and sever-
ity of EC conditions. In the present study, correlation of vitamin 
D metabolites with other parameters such as blood pressure, 
cytokine/chemokines, and metabolic hormones was calculated. 
Upon considering significance (p  <  0.002) with Bonferroni 
adjustment, negative correlation was observed between vitamin 
D metabolites [total 25(OH)D and 1,25(OH)2D] and clinical 
characteristics such as systolic blood pressure and diastolic 
blood pressure. However, only 25(OH)D is negatively correlated 
with serum creatinine and serum urea levels. When significance 
(p <  0.05) was considered, 25(OH)D is negatively correlated 
with UMP and positively correlated with inflammatory markers 
MCP-1, MIP-1α, MIP-1β, and TNF-alpha. Similarly, 1,25(OH)2D 
is negatively correlated with creatinine, urea, and ghrelin and 
positively correlated with IL-9, IL-17 IFN-γ, and MIP-1β. These 
data confirm that correlation of lower vitamin D and its metabo-
lite levels with clinical characteristics and laboratory parameters 
of GH, PE, and EC in Indian pregnant women. Data from the 
present study confirm that there is a strong association between 
cytokines and vitamin D metabolites. Recently, Zerofsky et  al. 
reported that vitamin D supplementation with 2,000  IU/day 
associated with increased regulatory T  cell immunity (58), 
which may prevent the adverse outcomes caused by excess 
inflammation.
After that it tried to find if there is any correlation between 
groupwise correlations of blood pressure vs circulatory mark-
ers. In the HP group, DBP negatively correlated with IFN-γ. 
However, in the case of the HDP group, both SBP and DBP 
positively correlated with serum creatinine and serum urea, 
and hypertensive disorders in pregnant women DBP positively 
correlated with urinary microprotein. These findings suggest 
that decreased vitamin D levels may increase blood pressure 
in pregnant women. Our results are consistent with the previous 
literature (7).
Finally, logistic regression analysis was performed to get 
causal relationship between hypertension disorders and HP. 
The analysis revealed that eotaxin, MCP-1, and vitamin D 
metabolites 25(OH)D and 1,25(OH)2D were common predic-
tors of hypertensive disorders in pregnant women as compared 
with the HP group. Other cytokines/chemokines IL-1ra, IL-13, 
IL-17, INF-γ, TNF-α, and GIP were near to the significance 
levels. Future studies with large number of subjects will find the 
association of these abovementioned markers with vitamin D 
level in pregnant women.
Although some good correlations have been found between 
vitamin D metabolites and cytokine levels, the present study 
had some limitations. It was a single-center one-point study 
among South Indian subjects. Thus, the results may not be 
generalizable to other population. Another limitation of this 
study is the relatively small number of cases, but these numbers 
were found to be comparable to previous case–control studies 
(59, 60). The issue of whether GH and PE are separate disorders 
with the common clinical sign of hypertension, or part of a spec-
trum, has not been settled. Our findings strongly suggest that 
these hypertensive pregnancy disorders should be addressed 
separately with large number of subjects in future studies. 
Most importantly, as an observational study, this study is more 
hypothesis generating and does not address causality. Another 
limitation of this study is that we have measured freely available 
circulatory cytokine/chemokine levels and not measured those 
from micro-/macrovesicles and exosomes, which may excrete 
during stress conditions in pregnancy. Finally, we recognize 
the continued uncertainty as the optimal method of measuring 
25(OH)D levels (61, 62); however, we used the established gold 
standard UPLC/APCI/HRMS method to measure six vitamin 
D metabolites and total 25(OH)D and 1,25(OH)2 D levels of 
each participant.
cOnclUsiOn
Our data suggest that vitamin D deficiency may play major role 
in progression of HDP. Circulatory cytokine/chemokine levels 
were altered in the HDP group. Furthermore, our analyses 
suggest that lower vitamin D metabolites were associated with 
altered cytokines/chemokines and metabolic hormones in HDP. 
Eotaxin, MCP-1, 25(OH)D, and 1,25(OH)2D levels were predic-
tors of HDP as compared to the HP group. However, future 
studies with large number of subjects are needed to confirm 
these findings.
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